Key result
The proportion of post-myocardial infarction patients treated with lipid-lowering drugs rose significantly to 88.1% in 2005 compared to 47.8% in 1999-2000.
Why the study?
The study aimed to describe the status and developments of cardiovascular pharmacotherapy in patients after myocardial infarction and/or revascularization in the Czech Republic over the past 5 and 10 years.
Cross-Sectional (n=857)
Yes
Absolute Event Rate: 88.1% vs 47.8%
p-value: p=<0.001
The study demonstrates significant improvements in the utilization of secondary prevention pharmacotherapy (statins, beta-blockers, ACE inhibitors) in the Czech Republic between 1995 and 2005, though control of hypertension and obesity remains suboptimal.
Observational trends in post-MI pharmacotherapy may reflect evolving practice; leaves open effects on outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Widimský et al. (2006) conducted a cross-sectional in Myocardial infarction and/or myocardial revascularization (n=857). Cardiovascular pharmacotherapy in 2005 vs. Cardiovascular pharmacotherapy in 1999-2000 was evaluated on Proportion of patients treated with lipid-lowering drugs (p=<0.001). The proportion of post-myocardial infarction patients treated with lipid-lowering drugs rose significantly to 88.1% in 2005 compared to 47.8% in 1999-2000.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: